Trial Outcomes & Findings for A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL (NCT NCT02055820)
NCT ID: NCT02055820
Last Updated: 2020-06-11
Results Overview
DLTs were reported according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0 (NCI CTCAE v4.0). Decrease in B cells, lymphopenia, and leukopenia caused by lymphopenia were not considered DLTs but instead were expected outcomes of study treatment. Any Grade \>/= 3 adverse event, that was attributed to having a reasonable possibility of being related to the combined administration of venetoclax plus R-CHOP or G-CHOP, that could not be attributed by the investigator to an alternative, clearly identifiable cause such as tumor progression, concurrent illness or medical condition, or concomitant medication and that occurred during the DLT observation period (start of venetoclax treatment through end of Cycle 2) was considered a DLT for dose-escalation purposes. Grade 3 or 4 neutropenia or thrombocytopenia identified on Day 1 of Cycle 2 or 3, resulting in dose delay were considered DLTs.
Recruitment status
COMPLETED
Study phase
PHASE1/PHASE2
Target enrollment
267 participants
Primary outcome timeframe
Start of venetoclax administration (Cycle 1 Day 4 or 3 days after first CHOP dose) up to end of Cycle 2 (cycle length = 21 days)
Results posted on
2020-06-11
Participant Flow
At start the trial had a randomised-controlled component, until July 2016 once the arm B (Gazyva) got closed following the publication of results of another trial. Since July 2016, the trial was single-arm, not randomised anymore, and kept including patients in only 1 arm (Arm A, rituximab).
The data reported for participant flow is based on safety population, which includes all participants who received at least one dose of study medication.
Participant milestones
| Measure |
Venetoclax 200 mg +R-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 400 mg +R-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 600 mg +R-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg +R-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg +R-CHOP Phase II
Phase II: Participants received 6 cycles of CHOP and 8 cycles of venetoclax (at dose determined in Phase I) + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 200 mg +G-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 400 mg +G-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 600 mg +G-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg + G-CHOP A
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. In this arm venetoclax was administered as follows: Cycle 1 Days 4-10; Cycles 2-8 Days 1-10, Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg +G-CHOP B
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. In this arm venetoclax was administered as follows: Cycle 1 Days 4-8; Cycles 2-8 Days 1-5. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Phase I: Dose-Finding
STARTED
|
7
|
3
|
8
|
6
|
0
|
7
|
7
|
6
|
6
|
6
|
|
Phase I: Dose-Finding
COMPLETED
|
6
|
3
|
7
|
3
|
0
|
5
|
5
|
6
|
6
|
6
|
|
Phase I: Dose-Finding
NOT COMPLETED
|
1
|
0
|
1
|
3
|
0
|
2
|
2
|
0
|
0
|
0
|
|
Phase II: Expansion
STARTED
|
0
|
0
|
0
|
0
|
208
|
0
|
0
|
0
|
0
|
0
|
|
Phase II: Expansion
COMPLETED
|
0
|
0
|
0
|
0
|
159
|
0
|
0
|
0
|
0
|
0
|
|
Phase II: Expansion
NOT COMPLETED
|
0
|
0
|
0
|
0
|
49
|
0
|
0
|
0
|
0
|
0
|
Reasons for withdrawal
| Measure |
Venetoclax 200 mg +R-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 400 mg +R-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 600 mg +R-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg +R-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg +R-CHOP Phase II
Phase II: Participants received 6 cycles of CHOP and 8 cycles of venetoclax (at dose determined in Phase I) + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 200 mg +G-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 400 mg +G-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 600 mg +G-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg + G-CHOP A
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. In this arm venetoclax was administered as follows: Cycle 1 Days 4-10; Cycles 2-8 Days 1-10, Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg +G-CHOP B
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. In this arm venetoclax was administered as follows: Cycle 1 Days 4-8; Cycles 2-8 Days 1-5. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Phase I: Dose-Finding
Death
|
1
|
0
|
1
|
2
|
0
|
1
|
1
|
0
|
0
|
0
|
|
Phase I: Dose-Finding
Withdrawal by Subject
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
|
Phase I: Dose-Finding
Lost to Follow-up
|
0
|
0
|
0
|
1
|
0
|
0
|
1
|
0
|
0
|
0
|
|
Phase II: Expansion
Death
|
0
|
0
|
0
|
0
|
33
|
0
|
0
|
0
|
0
|
0
|
|
Phase II: Expansion
Lost to Follow-up
|
0
|
0
|
0
|
0
|
4
|
0
|
0
|
0
|
0
|
0
|
|
Phase II: Expansion
Withdrawal by Subject
|
0
|
0
|
0
|
0
|
12
|
0
|
0
|
0
|
0
|
0
|
Baseline Characteristics
A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCL
Baseline characteristics by cohort
| Measure |
Venetoclax 200 mg +R-CHOP
n=7 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 400 mg +R-CHOP
n=3 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 600 mg +R-CHOP
n=8 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg +R-CHOP
n=6 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg +R-CHOP Phase II
n=208 Participants
Phase II: Participants received 6 cycles of CHOP and 8 cycles of venetoclax (at dose determined in Phase I) + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 200 mg +G-CHOP
n=7 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 400 mg +G-CHOP
n=7 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 600 mg +G-CHOP
n=6 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg + G-CHOP A
n=6 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. In this arm venetoclax was administered as follows: Cycle 1 Days 4-10; Cycles 2-8 Days 1-10, Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg +G-CHOP B
n=6 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. In this arm venetoclax was administered as follows: Cycle 1 Days 4-8; Cycles 2-8 Days 1-5. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Total
n=264 Participants
Total of all reporting groups
|
|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ethnicity (NIH/OMB)
Unknown or Not Reported
|
1 Participants
n=93 Participants
|
2 Participants
n=4 Participants
|
6 Participants
n=27 Participants
|
3 Participants
n=483 Participants
|
53 Participants
n=36 Participants
|
1 Participants
n=10 Participants
|
4 Participants
n=115 Participants
|
2 Participants
n=40 Participants
|
1 Participants
n=8 Participants
|
0 Participants
n=62 Participants
|
73 Participants
n=95 Participants
|
|
Race (NIH/OMB)
American Indian or Alaska Native
|
0 Participants
n=93 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=27 Participants
|
0 Participants
n=483 Participants
|
0 Participants
n=36 Participants
|
0 Participants
n=10 Participants
|
0 Participants
n=115 Participants
|
0 Participants
n=40 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=62 Participants
|
0 Participants
n=95 Participants
|
|
Race (NIH/OMB)
Asian
|
0 Participants
n=93 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=27 Participants
|
0 Participants
n=483 Participants
|
5 Participants
n=36 Participants
|
0 Participants
n=10 Participants
|
1 Participants
n=115 Participants
|
0 Participants
n=40 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=62 Participants
|
6 Participants
n=95 Participants
|
|
Age, Continuous
|
67.0 Years
STANDARD_DEVIATION 9.2 • n=93 Participants
|
61.0 Years
STANDARD_DEVIATION 13.1 • n=4 Participants
|
57.0 Years
STANDARD_DEVIATION 9.5 • n=27 Participants
|
56.3 Years
STANDARD_DEVIATION 11.9 • n=483 Participants
|
61.4 Years
STANDARD_DEVIATION 12.8 • n=36 Participants
|
52.1 Years
STANDARD_DEVIATION 16.2 • n=10 Participants
|
60.9 Years
STANDARD_DEVIATION 6.3 • n=115 Participants
|
66.7 Years
STANDARD_DEVIATION 4.2 • n=40 Participants
|
60.5 Years
STANDARD_DEVIATION 13.7 • n=8 Participants
|
66.8 Years
STANDARD_DEVIATION 6.7 • n=62 Participants
|
61.2 Years
STANDARD_DEVIATION 12.5 • n=95 Participants
|
|
Sex: Female, Male
Female
|
3 Participants
n=93 Participants
|
2 Participants
n=4 Participants
|
2 Participants
n=27 Participants
|
2 Participants
n=483 Participants
|
94 Participants
n=36 Participants
|
2 Participants
n=10 Participants
|
5 Participants
n=115 Participants
|
4 Participants
n=40 Participants
|
4 Participants
n=8 Participants
|
2 Participants
n=62 Participants
|
120 Participants
n=95 Participants
|
|
Sex: Female, Male
Male
|
4 Participants
n=93 Participants
|
1 Participants
n=4 Participants
|
6 Participants
n=27 Participants
|
4 Participants
n=483 Participants
|
114 Participants
n=36 Participants
|
5 Participants
n=10 Participants
|
2 Participants
n=115 Participants
|
2 Participants
n=40 Participants
|
2 Participants
n=8 Participants
|
4 Participants
n=62 Participants
|
144 Participants
n=95 Participants
|
|
Ethnicity (NIH/OMB)
Hispanic or Latino
|
0 Participants
n=93 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=27 Participants
|
0 Participants
n=483 Participants
|
4 Participants
n=36 Participants
|
0 Participants
n=10 Participants
|
0 Participants
n=115 Participants
|
0 Participants
n=40 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=62 Participants
|
4 Participants
n=95 Participants
|
|
Ethnicity (NIH/OMB)
Not Hispanic or Latino
|
6 Participants
n=93 Participants
|
1 Participants
n=4 Participants
|
2 Participants
n=27 Participants
|
3 Participants
n=483 Participants
|
151 Participants
n=36 Participants
|
6 Participants
n=10 Participants
|
3 Participants
n=115 Participants
|
4 Participants
n=40 Participants
|
5 Participants
n=8 Participants
|
6 Participants
n=62 Participants
|
187 Participants
n=95 Participants
|
|
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
|
0 Participants
n=93 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=27 Participants
|
0 Participants
n=483 Participants
|
3 Participants
n=36 Participants
|
0 Participants
n=10 Participants
|
0 Participants
n=115 Participants
|
0 Participants
n=40 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=62 Participants
|
3 Participants
n=95 Participants
|
|
Race (NIH/OMB)
Black or African American
|
0 Participants
n=93 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=27 Participants
|
0 Participants
n=483 Participants
|
4 Participants
n=36 Participants
|
0 Participants
n=10 Participants
|
0 Participants
n=115 Participants
|
0 Participants
n=40 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=62 Participants
|
4 Participants
n=95 Participants
|
|
Race (NIH/OMB)
White
|
6 Participants
n=93 Participants
|
1 Participants
n=4 Participants
|
2 Participants
n=27 Participants
|
2 Participants
n=483 Participants
|
154 Participants
n=36 Participants
|
7 Participants
n=10 Participants
|
2 Participants
n=115 Participants
|
4 Participants
n=40 Participants
|
5 Participants
n=8 Participants
|
4 Participants
n=62 Participants
|
187 Participants
n=95 Participants
|
|
Race (NIH/OMB)
More than one race
|
0 Participants
n=93 Participants
|
0 Participants
n=4 Participants
|
0 Participants
n=27 Participants
|
0 Participants
n=483 Participants
|
0 Participants
n=36 Participants
|
0 Participants
n=10 Participants
|
0 Participants
n=115 Participants
|
0 Participants
n=40 Participants
|
0 Participants
n=8 Participants
|
0 Participants
n=62 Participants
|
0 Participants
n=95 Participants
|
|
Race (NIH/OMB)
Unknown or Not Reported
|
1 Participants
n=93 Participants
|
2 Participants
n=4 Participants
|
6 Participants
n=27 Participants
|
4 Participants
n=483 Participants
|
42 Participants
n=36 Participants
|
0 Participants
n=10 Participants
|
4 Participants
n=115 Participants
|
2 Participants
n=40 Participants
|
1 Participants
n=8 Participants
|
2 Participants
n=62 Participants
|
64 Participants
n=95 Participants
|
PRIMARY outcome
Timeframe: Start of venetoclax administration (Cycle 1 Day 4 or 3 days after first CHOP dose) up to end of Cycle 2 (cycle length = 21 days)Population: Safety population: All participants who enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population for safety analyses. Here, participants in the Dose Finding phase were analyzed.
DLTs were reported according to the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0 (NCI CTCAE v4.0). Decrease in B cells, lymphopenia, and leukopenia caused by lymphopenia were not considered DLTs but instead were expected outcomes of study treatment. Any Grade \>/= 3 adverse event, that was attributed to having a reasonable possibility of being related to the combined administration of venetoclax plus R-CHOP or G-CHOP, that could not be attributed by the investigator to an alternative, clearly identifiable cause such as tumor progression, concurrent illness or medical condition, or concomitant medication and that occurred during the DLT observation period (start of venetoclax treatment through end of Cycle 2) was considered a DLT for dose-escalation purposes. Grade 3 or 4 neutropenia or thrombocytopenia identified on Day 1 of Cycle 2 or 3, resulting in dose delay were considered DLTs.
Outcome measures
| Measure |
Venetoclax 200 mg + R-CHOP
n=7 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 400 mg + R-CHOP
n=3 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 600 mg + R-CHOP
n=8 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800mg + R-CHOP
n=6 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 200mg + G-CHOP
n=7 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 400mg + G-CHOP
n=7 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 600mg + G-CHOP
n=6 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg + G-CHOP A
n=6 Participants
Venetoclax + G-CHOP 800 mg A Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. In this arm venetoclax was delivered in Cycle 1 on Days 4-10 and Cycles 2-8 on Days 1-10. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg + G-CHOP B
n=6 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. In this arm ventoclax was delivered in Cycle 1 on Days 4-8 and Cycles 2-8 on Days 1-5. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg + G-CHOP B
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. In this arm ventoclax was delivered in Cycle 1 on Days 4-8 and Cycles 2-8 on Days 1-5. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Safety: Number of Participants With Dose-Limiting Toxicities (DLTs)
|
1 Participants
|
0 Participants
|
1 Participants
|
0 Participants
|
2 Participants
|
1 Participants
|
1 Participants
|
0 Participants
|
0 Participants
|
—
|
PRIMARY outcome
Timeframe: Baseline up to end of treatment (up to approximately 6 months)Population: Intent-to-treat (ITT) population: All participants who enrolled in the study were included in the ITT population. Data reported for all participants for whom data were available.
CR was defined as follows according to modified Lugano classification for PET/CT-based response: Lymph nodes and extra-lymphatic sites with score 1, 2, or 3 with or without a residual mass on 5-point scale with 1) no uptake above background; 2) uptake \</= mediastinum; 3) uptake \< mediastinum but \</= liver. No evidence of fluorodeoxyglucose (FDG)-uptake disease in marrow. If the bone marrow was involved by lymphoma prior to treatment, the infiltrate must have cleared on repeat bone marrow biopsy
Outcome measures
| Measure |
Venetoclax 200 mg + R-CHOP
n=211 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 400 mg + R-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 600 mg + R-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800mg + R-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 200mg + G-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 400mg + G-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 600mg + G-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg + G-CHOP A
Venetoclax + G-CHOP 800 mg A Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. In this arm venetoclax was delivered in Cycle 1 on Days 4-10 and Cycles 2-8 on Days 1-10. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg + G-CHOP B
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. In this arm ventoclax was delivered in Cycle 1 on Days 4-8 and Cycles 2-8 on Days 1-5. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg + G-CHOP B
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. In this arm ventoclax was delivered in Cycle 1 on Days 4-8 and Cycles 2-8 on Days 1-5. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Percentage of Previously Untreated DLBCL Participants With Complete Response (CR) Defined by Positron Emission Tomography-Computed Tomography (PET/CT) Scan Using the Modified Lugano Classification Assessed by Independent Review Committee (IRC)
|
68.2 Percentage of participants
Interval 61.5 to 74.47
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
PRIMARY outcome
Timeframe: Baseline up to end of treatment (up to approximately 6 months)Population: Intent-to-treat (ITT) population: All participants who enrolled in the study were included in the ITT population. Data reported for subgroup of the ITT, DE Participants.
CR was defined as follows according to modified Lugano classification for PET/CT-based response: Lymph nodes and extra-lymphatic sites with score 1, 2, or 3 with or without a residual mass on 5-point scale with 1) no uptake above background; 2) uptake \</= mediastinum; 3) uptake \< mediastinum but \</= liver. No evidence of fluorodeoxyglucose (FDG)-uptake disease in marrow. If the bone marrow was involved by lymphoma prior to treatment, the infiltrate must have cleared on repeat bone marrow biopsy.
Outcome measures
| Measure |
Venetoclax 200 mg + R-CHOP
n=81 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 400 mg + R-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 600 mg + R-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800mg + R-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 200mg + G-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 400mg + G-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 600mg + G-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg + G-CHOP A
Venetoclax + G-CHOP 800 mg A Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. In this arm venetoclax was delivered in Cycle 1 on Days 4-10 and Cycles 2-8 on Days 1-10. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg + G-CHOP B
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. In this arm ventoclax was delivered in Cycle 1 on Days 4-8 and Cycles 2-8 on Days 1-5. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg + G-CHOP B
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. In this arm ventoclax was delivered in Cycle 1 on Days 4-8 and Cycles 2-8 on Days 1-5. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Percentage of Participants With CR Defined by PET/CT Scan in Previously Untreated DLBCL Co-Expressing Both Bcl-2 and c-Myc Proteins (DE-DLBCL) Participants Assessed by IRC
|
66.7 Percentage of participants
Interval 55.32 to 76.76
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Predose (within 30 minutes) & 2, 4, 6, 8 hours (Hr) postdose on Cycle 1 Day 4 (cycle length = 21 days)Population: PK evaluable population: All patients who received study drug and provided at least one post-treatment PK sample for whom data were available. Reporting according to study drug received. One participant mistakenly received only 100 mg instead of the planned 200 mg dose and was reported in a separate arm for PK outcome measures.
AUC was calculated based on measurement of venetoclax concentration in plasma over time. Venetoclax exposure was pooled across Phase I and II for the R-CHOP 800 mg cohorts. Data are reported as hour\*micrograms per milliliter (hr\*mcg/mL)
Outcome measures
| Measure |
Venetoclax 200 mg + R-CHOP
n=1 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 400 mg + R-CHOP
n=6 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 600 mg + R-CHOP
n=4 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800mg + R-CHOP
n=8 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 200mg + G-CHOP
n=124 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 400mg + G-CHOP
n=7 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 600mg + G-CHOP
n=7 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg + G-CHOP A
n=6 Participants
Venetoclax + G-CHOP 800 mg A Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. In this arm venetoclax was delivered in Cycle 1 on Days 4-10 and Cycles 2-8 on Days 1-10. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg + G-CHOP B
n=10 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. In this arm ventoclax was delivered in Cycle 1 on Days 4-8 and Cycles 2-8 on Days 1-5. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg + G-CHOP B
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. In this arm ventoclax was delivered in Cycle 1 on Days 4-8 and Cycles 2-8 on Days 1-5. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Venetoclax Plasma PK: Area Under the Plasma Concentration-Time Curve (AUC)
|
.66 hr*mcg/mL
Standard Deviation NA
N/A as there is only one participant in this cohort
|
2.51 hr*mcg/mL
Standard Deviation .97
|
3.87 hr*mcg/mL
Standard Deviation 2.41
|
3.70 hr*mcg/mL
Standard Deviation 1.59
|
4.51 hr*mcg/mL
Standard Deviation 2.32
|
2.55 hr*mcg/mL
Standard Deviation 1.13
|
4.33 hr*mcg/mL
Standard Deviation 1.31
|
5.13 hr*mcg/mL
Standard Deviation 2.41
|
6.20 hr*mcg/mL
Standard Deviation 1.71
|
—
|
SECONDARY outcome
Timeframe: Predose (within 30 minutes) & 2, 4, 6, 8 Hr postdose on Cycle 1 Day 4 (cycle length = 21 days)Population: PK evaluable population: All patients who received study drug and provided at least one post-treatment PK sample for whom data were available. Reporting according to study drug received. One participant mistakenly received only 100 mg instead of the planned 200 mg dose and was reported in a separate arm for PK outcome measures.
Tmax was determined based on measurement of venetoclax concentrations in plasma over time. Venetoclax exposure was pooled across Phase I and II for the R-CHOP 800 mg cohorts.
Outcome measures
| Measure |
Venetoclax 200 mg + R-CHOP
n=1 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 400 mg + R-CHOP
n=6 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 600 mg + R-CHOP
n=4 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800mg + R-CHOP
n=8 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 200mg + G-CHOP
n=124 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 400mg + G-CHOP
n=7 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 600mg + G-CHOP
n=7 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg + G-CHOP A
n=6 Participants
Venetoclax + G-CHOP 800 mg A Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. In this arm venetoclax was delivered in Cycle 1 on Days 4-10 and Cycles 2-8 on Days 1-10. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg + G-CHOP B
n=10 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. In this arm ventoclax was delivered in Cycle 1 on Days 4-8 and Cycles 2-8 on Days 1-5. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg + G-CHOP B
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. In this arm ventoclax was delivered in Cycle 1 on Days 4-8 and Cycles 2-8 on Days 1-5. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Venetoclax Plasma PK: Time to Maximum Observed Plasma Concentration (Tmax)
|
4.0 Hour
Standard Deviation NA
N/A as there is only one participant in this cohort
|
4.59 Hour
Standard Deviation 1.08
|
6.50 Hour
Standard Deviation 1.91
|
5.52 Hour
Standard Deviation 2.07
|
5.53 Hour
Standard Deviation 1.55
|
5.72 Hour
Standard Deviation 1.42
|
6.56 Hour
Standard Deviation 1.51
|
5.30 Hour
Standard Deviation 2.38
|
5.79 Hour
Standard Deviation 1.47
|
—
|
SECONDARY outcome
Timeframe: Predose (within 30 minutes) & 2, 4, 6, 8 Hr postdose on Cycle 1 Day 4 (cycle length = 21 days)Population: PK evaluable population: All patients who received study drug and provided at least one post-treatment PK sample for whom data were available. Reporting according to study drug received. One participant mistakenly received only 100 mg instead of the planned 200 mg dose and was reported in a separate arm for PK outcome measures.
Cmax was determined based on measurement of venetoclax concentrations in plasma over time. Venetoclax exposure was pooled across Phase I and II for the R-CHOP 800 mg cohorts. Data are reported as micrograms per milliliter
Outcome measures
| Measure |
Venetoclax 200 mg + R-CHOP
n=1 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 400 mg + R-CHOP
n=6 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 600 mg + R-CHOP
n=4 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800mg + R-CHOP
n=8 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 200mg + G-CHOP
n=124 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 400mg + G-CHOP
n=7 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 600mg + G-CHOP
n=7 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg + G-CHOP A
n=6 Participants
Venetoclax + G-CHOP 800 mg A Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. In this arm venetoclax was delivered in Cycle 1 on Days 4-10 and Cycles 2-8 on Days 1-10. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg + G-CHOP B
n=10 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. In this arm ventoclax was delivered in Cycle 1 on Days 4-8 and Cycles 2-8 on Days 1-5. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg + G-CHOP B
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. In this arm ventoclax was delivered in Cycle 1 on Days 4-8 and Cycles 2-8 on Days 1-5. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Venetoclax Plasma PK: Maximum Observed Plasma Concentration (Cmax)
|
.09 Ug/ML
Standard Deviation NA
N/A as there is only one participant in this cohort
|
.58 Ug/ML
Standard Deviation .32
|
.92 Ug/ML
Standard Deviation .64
|
.85 Ug/ML
Standard Deviation .33
|
1.15 Ug/ML
Standard Deviation .48
|
.52 Ug/ML
Standard Deviation .21
|
1.26 Ug/ML
Standard Deviation .30
|
1.00 Ug/ML
Standard Deviation .58
|
1.54 Ug/ML
Standard Deviation .37
|
—
|
SECONDARY outcome
Timeframe: Predose (within 30 minutes) & 2, 4, 6, 8 Hr postdose on Cycle 1 Day 4 (cycle length = 21 days)Population: PK evaluable population: All patients who received study drug and provided at least one post-treatment PK sample for whom data were available. Reporting according to study drug received. One participant mistakenly received only 100 mg instead of the planned 200 mg dose and was reported in a separate arm for PK outcome measures.
Cmin was determined based on measurement of venetoclax concentrations in plasma over time. Venetoclax exposure was pooled across Phase I and II for the R-CHOP 800 mg cohorts.
Outcome measures
| Measure |
Venetoclax 200 mg + R-CHOP
n=1 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 400 mg + R-CHOP
n=3 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 600 mg + R-CHOP
n=2 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800mg + R-CHOP
n=4 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 200mg + G-CHOP
n=126 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 400mg + G-CHOP
n=7 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 600mg + G-CHOP
n=5 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg + G-CHOP A
n=5 Participants
Venetoclax + G-CHOP 800 mg A Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. In this arm venetoclax was delivered in Cycle 1 on Days 4-10 and Cycles 2-8 on Days 1-10. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg + G-CHOP B
n=6 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. In this arm ventoclax was delivered in Cycle 1 on Days 4-8 and Cycles 2-8 on Days 1-5. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg + G-CHOP B
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. In this arm ventoclax was delivered in Cycle 1 on Days 4-8 and Cycles 2-8 on Days 1-5. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Venetoclax Plasma PK: Minimum Plasma Concentration (Cmin) Within the Dosing Interval
|
0.0714 mcg/mL
Standard Deviation 0.00
|
0.522 mcg/mL
Standard Deviation 0.441
|
0.253 mcg/mL
Standard Deviation 0.247
|
0.387 mcg/mL
Standard Deviation 0.141
|
0.640 mcg/mL
Standard Deviation 0.451
|
0.134 mcg/mL
Standard Deviation 0.107
|
0.395 mcg/mL
Standard Deviation 0.381
|
0.612 mcg/mL
Standard Deviation 0.535
|
0.628 mcg/mL
Standard Deviation 0.395
|
—
|
SECONDARY outcome
Timeframe: Predose (within 30 minutes) and 0.5, 1, 2, 4, 6 Hr after prednisone dose on Day 1 of Cycle 1 and 2 (cycle length = 21 days)Population: PK evaluable population: All participants who received study drug and provided at least one post-treatment PK sample. A similar dose strength of prednisone (100 mg) was administered across the treatment arms/venetoclax dose groups. Hence, the data are presented as an overall summary in Cycles 1 and 2.
AUC was determined based on measurement of Predisone concentrations in plasma over time.
Outcome measures
| Measure |
Venetoclax 200 mg + R-CHOP
n=54 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 400 mg + R-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 600 mg + R-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800mg + R-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 200mg + G-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 400mg + G-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 600mg + G-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg + G-CHOP A
Venetoclax + G-CHOP 800 mg A Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. In this arm venetoclax was delivered in Cycle 1 on Days 4-10 and Cycles 2-8 on Days 1-10. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg + G-CHOP B
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. In this arm ventoclax was delivered in Cycle 1 on Days 4-8 and Cycles 2-8 on Days 1-5. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg + G-CHOP B
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. In this arm ventoclax was delivered in Cycle 1 on Days 4-8 and Cycles 2-8 on Days 1-5. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Prednisone Plasma PK: AUC
Cycle 1, Day 1
|
195 hr*mcg/mL
Standard Deviation 72.8
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Prednisone Plasma PK: AUC
Cycle 2, Day 1
|
184 hr*mcg/mL
Standard Deviation 81.2
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Predose (within 30 minutes) and 0.5, 1, 2, 4, 6 Hr after prednisone dose on Day 1 of Cycle 1 and 2 (cycle length = 21 days)Population: PK evaluable population: All patients who received study drug and provided at least one post-treatment PK sample for whom data were available. A similar dose strength of prednisone (100 mg) was administered across the treatment arms/venetoclax dose groups. Hence, the data are presented as an overall summary in Cycles 1 and 2.
Tmax was determined based on measurement of Predisone concentrations in plasma over time.
Outcome measures
| Measure |
Venetoclax 200 mg + R-CHOP
n=54 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 400 mg + R-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 600 mg + R-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800mg + R-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 200mg + G-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 400mg + G-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 600mg + G-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg + G-CHOP A
Venetoclax + G-CHOP 800 mg A Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. In this arm venetoclax was delivered in Cycle 1 on Days 4-10 and Cycles 2-8 on Days 1-10. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg + G-CHOP B
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. In this arm ventoclax was delivered in Cycle 1 on Days 4-8 and Cycles 2-8 on Days 1-5. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg + G-CHOP B
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. In this arm ventoclax was delivered in Cycle 1 on Days 4-8 and Cycles 2-8 on Days 1-5. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Prednisone Plasma PK: Tmax
Cycle 1, Day 1
|
2.19 Hour
Standard Deviation 1.61
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Prednisone Plasma PK: Tmax
Cycle 2, Day 1
|
3.80 Hour
Standard Deviation 2.52
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Predose (within 30 minutes) and 0.5, 1, 2, 4, 6 Hr after prednisone dose on Day 1 of Cycle 1 and 2 (cycle length = 21 days)Population: PK evaluable population: All patients who received study drug and provided at least one post-treatment PK sample for whom data were available. A similar dose strength of prednisone (100 mg) was administered across the treatment arms/venetoclax dose groups. Hence, the data are presented as an overall summary in Cycles 1 and 2.
Cmax was determined based on measurement of Predisone concentrations in plasma over time.
Outcome measures
| Measure |
Venetoclax 200 mg + R-CHOP
n=54 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 400 mg + R-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 600 mg + R-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800mg + R-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 200mg + G-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 400mg + G-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 600mg + G-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg + G-CHOP A
Venetoclax + G-CHOP 800 mg A Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. In this arm venetoclax was delivered in Cycle 1 on Days 4-10 and Cycles 2-8 on Days 1-10. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg + G-CHOP B
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. In this arm ventoclax was delivered in Cycle 1 on Days 4-8 and Cycles 2-8 on Days 1-5. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg + G-CHOP B
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. In this arm ventoclax was delivered in Cycle 1 on Days 4-8 and Cycles 2-8 on Days 1-5. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Prednisone Plasma PK: Cmax
Cycle 1, Day 1
|
49.9 Ng/ML
Standard Deviation 28.7
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Prednisone Plasma PK: Cmax
Cycle 2, Day 1
|
43.2 Ng/ML
Standard Deviation 17.6
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: End of Infusion on Cycle 1 Day 1 (cycle length = 21 days)Population: PK evaluable population: All patients who received study drug and provided at least one post-treatment PK sample for whom data were available. The Cmax of rituximab is presented at the 800 mg Venetoclax dose group. Hence, the data is not presented by the treatment arms/Venetoclax dose groups.
Cmax was determined using the post-dose rituximab plasma concentrations at the 800 mg Venetoclax Dose using the end of infusion time point on Cycle 1 Day 1.
Outcome measures
| Measure |
Venetoclax 200 mg + R-CHOP
n=7 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 400 mg + R-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 600 mg + R-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800mg + R-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 200mg + G-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 400mg + G-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 600mg + G-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg + G-CHOP A
Venetoclax + G-CHOP 800 mg A Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. In this arm venetoclax was delivered in Cycle 1 on Days 4-10 and Cycles 2-8 on Days 1-10. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg + G-CHOP B
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. In this arm ventoclax was delivered in Cycle 1 on Days 4-8 and Cycles 2-8 on Days 1-5. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg + G-CHOP B
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. In this arm ventoclax was delivered in Cycle 1 on Days 4-8 and Cycles 2-8 on Days 1-5. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Rituximab PK: Cmax
|
173 mcg/mL
Standard Deviation 39.4
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Pre-dose on Cycle 2 Day 1 (cycle length = 21 days)Population: PK evaluable population: All patients who received study drug and provided at least one post-treatment PK sample for whom data were available. The Cmin of rituximab is presented at the 800 mg Venetoclax dose group. Hence, the data is not presented by the treatment arms/Venetoclax dose groups.
Cmin was determined using the pre-dose rituximab plasma concentrations at the 800 mg Venetoclax Dose on Day 1 of Cycle 2.
Outcome measures
| Measure |
Venetoclax 200 mg + R-CHOP
n=8 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 400 mg + R-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 600 mg + R-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800mg + R-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 200mg + G-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 400mg + G-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 600mg + G-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg + G-CHOP A
Venetoclax + G-CHOP 800 mg A Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. In this arm venetoclax was delivered in Cycle 1 on Days 4-10 and Cycles 2-8 on Days 1-10. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg + G-CHOP B
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. In this arm ventoclax was delivered in Cycle 1 on Days 4-8 and Cycles 2-8 on Days 1-5. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg + G-CHOP B
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. In this arm ventoclax was delivered in Cycle 1 on Days 4-8 and Cycles 2-8 on Days 1-5. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Rituximab PK: Cmin Within the Dosing Interval
|
26.1 mcg/mL
Standard Deviation 13
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: End of Infusion on Cycle 1 Day 1 (cycle length = 21 days)Population: PK evaluable population: All patients who received study drug and provided at least one post-treatment PK sample for whom data were available. The Cmax of obinutuzumab is presented at the 800 mg Venetoclax dose group. Hence, the data is not presented by the treatment arms/Venetoclax dose groups.
Cmax was determined using the post-dose obinutuzumab plasma concentrations at the 800 mg Venetoclax Dose using the end of infusion time point on Cycle 1 Day 1.
Outcome measures
| Measure |
Venetoclax 200 mg + R-CHOP
n=10 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 400 mg + R-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 600 mg + R-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800mg + R-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 200mg + G-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 400mg + G-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 600mg + G-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg + G-CHOP A
Venetoclax + G-CHOP 800 mg A Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. In this arm venetoclax was delivered in Cycle 1 on Days 4-10 and Cycles 2-8 on Days 1-10. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg + G-CHOP B
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. In this arm ventoclax was delivered in Cycle 1 on Days 4-8 and Cycles 2-8 on Days 1-5. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg + G-CHOP B
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. In this arm ventoclax was delivered in Cycle 1 on Days 4-8 and Cycles 2-8 on Days 1-5. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Obinutuzumab PK: Cmax
|
326 mcg/mL
Standard Deviation 76
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: End of Infusion on Cycle 1 Day 1 (cycle length = 21 days)Population: PK evaluable population: All patients who received study drug and provided at least one post-treatment PK sample for whom data were available. Given a single dose strength of Cyclophosphamide was administered across the different Venetoclax dose groups and treatment arms, hence the data are presented as an overall summary.
Cmax was determined using the post-dose Cyclophosphamide plasma concentrations on Cycle 1 Day 1.
Outcome measures
| Measure |
Venetoclax 200 mg + R-CHOP
n=36 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 400 mg + R-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 600 mg + R-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800mg + R-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 200mg + G-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 400mg + G-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 600mg + G-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg + G-CHOP A
Venetoclax + G-CHOP 800 mg A Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. In this arm venetoclax was delivered in Cycle 1 on Days 4-10 and Cycles 2-8 on Days 1-10. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg + G-CHOP B
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. In this arm ventoclax was delivered in Cycle 1 on Days 4-8 and Cycles 2-8 on Days 1-5. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg + G-CHOP B
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. In this arm ventoclax was delivered in Cycle 1 on Days 4-8 and Cycles 2-8 on Days 1-5. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Cyclophosphamide PK: Cmax
|
32.1 mcg/mL
Standard Deviation 7.51
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: End of Infusion on Cycle 1 Day 1 (cycle length = 21 days)Population: PK evaluable population: All patients who received study drug and provided at least one post-treatment PK sample for whom data were available. Given a single dose strength of Doxorubicin was administered across the different Venetoclax dose groups and treatment arms, hence the data are presented as an overall summary.
Cmax was determined using the post-dose Doxorubicin plasma concentrations.
Outcome measures
| Measure |
Venetoclax 200 mg + R-CHOP
n=24 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 400 mg + R-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 600 mg + R-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800mg + R-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 200mg + G-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 400mg + G-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 600mg + G-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg + G-CHOP A
Venetoclax + G-CHOP 800 mg A Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. In this arm venetoclax was delivered in Cycle 1 on Days 4-10 and Cycles 2-8 on Days 1-10. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg + G-CHOP B
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. In this arm ventoclax was delivered in Cycle 1 on Days 4-8 and Cycles 2-8 on Days 1-5. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg + G-CHOP B
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. In this arm ventoclax was delivered in Cycle 1 on Days 4-8 and Cycles 2-8 on Days 1-5. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Doxorubicin PK: Cmax
|
1260 mcg/mL
Standard Deviation 911
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: End of Infusion on Cycle 1 Day 1 (cycle length = 21 days)Population: PK evaluable population: All patients who received study drug and provided at least one post-treatment PK sample for whom data were available. Given a single dose strength of Vincristine was administered across the different Venetoclax dose groups and treatment arms, hence the data are presented as an overall summary.
Cmax was determined using the post-dose Vincristine plasma concentrations.
Outcome measures
| Measure |
Venetoclax 200 mg + R-CHOP
n=28 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 400 mg + R-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 600 mg + R-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800mg + R-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 200mg + G-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 400mg + G-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 600mg + G-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg + G-CHOP A
Venetoclax + G-CHOP 800 mg A Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. In this arm venetoclax was delivered in Cycle 1 on Days 4-10 and Cycles 2-8 on Days 1-10. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg + G-CHOP B
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. In this arm ventoclax was delivered in Cycle 1 on Days 4-8 and Cycles 2-8 on Days 1-5. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg + G-CHOP B
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. In this arm ventoclax was delivered in Cycle 1 on Days 4-8 and Cycles 2-8 on Days 1-5. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Vincristine PK: Cmax
|
54.0 mcg/mL
Standard Deviation 44.6
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Baseline to end of treatment (up to approximately 6 months)Population: Intent-to-treat (ITT) population: All participants who enrolled in the study were included in the ITT population. Data reported for all participants for whom data were available.
Objective Response defined as PR (partial response) or CR (complete response) at end of treatment. CR: Lymph nodes and extra-lymphatic sites with score 1, 2 or 3 on a 5-point scale (with a higher score being a worse outcome). No evidence of fluorodeoxyglucose (FDG)-uptake disease in marrow. If the bone marrow was involved by lymphoma prior to treatment, the infiltrate must have cleared on repeat bone marrow biopsy. PR: Lymph nodes and extralymphatic sites with score of 4 or 5 on the 5-point scale with reduced uptake compared with baseline and residual mass(es) of any size. CT-based response criteria for PR must also be met. No new lesions. In bone marrow residual uptake could be higher than in normal marrow but must be reduced compared with baseline; persistent focal changes in the marrow to be considered for further evaluation with magnetic resonance imaging (MRI) or biopsy or an interval scan. OR=PR+CR
Outcome measures
| Measure |
Venetoclax 200 mg + R-CHOP
n=211 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 400 mg + R-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 600 mg + R-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800mg + R-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 200mg + G-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 400mg + G-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 600mg + G-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg + G-CHOP A
Venetoclax + G-CHOP 800 mg A Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. In this arm venetoclax was delivered in Cycle 1 on Days 4-10 and Cycles 2-8 on Days 1-10. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg + G-CHOP B
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. In this arm ventoclax was delivered in Cycle 1 on Days 4-8 and Cycles 2-8 on Days 1-5. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg + G-CHOP B
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. In this arm ventoclax was delivered in Cycle 1 on Days 4-8 and Cycles 2-8 on Days 1-5. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Percentage of Participants With Objective Response Defined as Partial Response (PR) or Complete Response (CR) Defined by Positron Emission Tomography-Computed Tomography (PET/CT) Using the Modified Lugano Classification Assessed by IRC
|
81.5 Percentage of Participants
Interval 75.61 to 86.51
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Month 12Population: Intent-to-treat (ITT) population: All participants who enrolled in the study were included in the ITT population. Data reported for all participants for whom data were available.
Progressive disease (PD) was determined using the modified Lugano classification criteria. For PET-CT-based PD: Score 4 (uptake moderately \> liver) or 5 (uptake markedly higher than liver and/or new lesions) with an increase in intensity of uptake from baseline in target nodes and nodal lesions, new FDG-uptake foci of extranodal lesions consistent with lymphoma at interim or end-of-treatment assessment, no non-measured lesions, new FDG-uptake foci consistent with lymphoma, new or recurrent FDG-uptake foci in bone marrow. For CT-based PD: \>/= 50% decrease in SPD of up to 6 target measureable nodes and extranodal sites; non-measured lesion should be absent/normal, have regressed, but not increased; no new lesions.
Outcome measures
| Measure |
Venetoclax 200 mg + R-CHOP
n=7 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 400 mg + R-CHOP
n=3 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 600 mg + R-CHOP
n=8 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800mg + R-CHOP
n=6 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 200mg + G-CHOP
n=211 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 400mg + G-CHOP
n=7 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 600mg + G-CHOP
n=7 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg + G-CHOP A
n=6 Participants
Venetoclax + G-CHOP 800 mg A Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. In this arm venetoclax was delivered in Cycle 1 on Days 4-10 and Cycles 2-8 on Days 1-10. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg + G-CHOP B
n=6 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. In this arm ventoclax was delivered in Cycle 1 on Days 4-8 and Cycles 2-8 on Days 1-5. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg + G-CHOP B
n=6 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. In this arm ventoclax was delivered in Cycle 1 on Days 4-8 and Cycles 2-8 on Days 1-5. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Percentage of Participants Who Are Alive and Without Disease Progression at Month 12
|
85.71 Percentage of Participants
Interval 59.79 to 100.0
|
100.00 Percentage of Participants
Interval 100.0 to 100.0
|
87.50 Percentage of Participants
Interval 64.58 to 100.0
|
66.67 Percentage of Participants
Interval 28.95 to 100.0
|
88.99 Percentage of Participants
Interval 82.65 to 92.1
|
100.00 Percentage of Participants
Interval 100.0 to 100.0
|
75.00 Percentage of Participants
Interval 32.57 to 100.0
|
100.00 Percentage of Participants
Interval 100.0 to 100.0
|
100.00 Percentage of Participants
Interval 100.0 to 100.0
|
100.00 Percentage of Participants
Interval 100.0 to 100.0
|
SECONDARY outcome
Timeframe: Baseline up to end of treatment (approx. 6 months)Population: Intent-to-treat (ITT) population: All participants who enrolled in the study were included in the ITT population. Data reported for all participants for whom data were available.
CR was defined as follows according to modified Lugano classification for CT-based response: Target nodes/nodal masses must have regressed to \</= 1.5 cm in longest transverse diameter of a lesion (LDi), no extra-lymphatic sites of disease, absence of non-measured lesions, organ enlargement must have regressed to normal, no new lesions, and if the bone marrow was involved by lymphoma prior to treatment, the infiltrate must have cleared on repeat bone marrow biopsy.
Outcome measures
| Measure |
Venetoclax 200 mg + R-CHOP
n=211 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 400 mg + R-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 600 mg + R-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800mg + R-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 200mg + G-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 400mg + G-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 600mg + G-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg + G-CHOP A
Venetoclax + G-CHOP 800 mg A Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. In this arm venetoclax was delivered in Cycle 1 on Days 4-10 and Cycles 2-8 on Days 1-10. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg + G-CHOP B
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. In this arm ventoclax was delivered in Cycle 1 on Days 4-8 and Cycles 2-8 on Days 1-5. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg + G-CHOP B
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. In this arm ventoclax was delivered in Cycle 1 on Days 4-8 and Cycles 2-8 on Days 1-5. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Percentage of Participants With CR Defined by Computed Tomography (CT) Scan Using the Modified Lugano Classification
|
37.4 Percentage of Participants
Interval 30.89 to 44.35
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Baseline up to approximately 36 monthsPopulation: Safety population: All patients who enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population for safety analyses
An adverse event is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An adverse event can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as adverse events.
Outcome measures
| Measure |
Venetoclax 200 mg + R-CHOP
n=7 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 400 mg + R-CHOP
n=3 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 600 mg + R-CHOP
n=8 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800mg + R-CHOP
n=6 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 200mg + G-CHOP
n=208 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 400mg + G-CHOP
n=7 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 600mg + G-CHOP
n=7 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg + G-CHOP A
n=6 Participants
Venetoclax + G-CHOP 800 mg A Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. In this arm venetoclax was delivered in Cycle 1 on Days 4-10 and Cycles 2-8 on Days 1-10. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg + G-CHOP B
n=6 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. In this arm ventoclax was delivered in Cycle 1 on Days 4-8 and Cycles 2-8 on Days 1-5. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg + G-CHOP B
n=6 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. In this arm ventoclax was delivered in Cycle 1 on Days 4-8 and Cycles 2-8 on Days 1-5. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Safety: Percentage of Participants With Adverse Events
|
100.00 Percentage of Participants
|
100.00 Percentage of Participants
|
100.00 Percentage of Participants
|
100.00 Percentage of Participants
|
99.0 Percentage of Participants
|
100.00 Percentage of Participants
|
100.00 Percentage of Participants
|
100.00 Percentage of Participants
|
100.00 Percentage of Participants
|
100.00 Percentage of Participants
|
SECONDARY outcome
Timeframe: Baseline up to Cycle 6 (cycle length = 21 days)Population: Safety population: All patients who enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population for safety analyses. Overall R-CHOP and G-CHOP arms were analyzed for this outcome measure.
Maintenance of relative dose intensity was defined as a dose intensity of \>/= 90%.
Outcome measures
| Measure |
Venetoclax 200 mg + R-CHOP
n=232 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 400 mg + R-CHOP
n=32 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 600 mg + R-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800mg + R-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 200mg + G-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 400mg + G-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 600mg + G-CHOP
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg + G-CHOP A
Venetoclax + G-CHOP 800 mg A Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. In this arm venetoclax was delivered in Cycle 1 on Days 4-10 and Cycles 2-8 on Days 1-10. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg + G-CHOP B
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. In this arm ventoclax was delivered in Cycle 1 on Days 4-8 and Cycles 2-8 on Days 1-5. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg + G-CHOP B
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. In this arm ventoclax was delivered in Cycle 1 on Days 4-8 and Cycles 2-8 on Days 1-5. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Safety: Percentage of Participants Maintaining Relative Dose Intensity of CHOP Chemotherapy
Cyclophosphamide
|
89.5 Percentage of participants
|
77.4 Percentage of participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Safety: Percentage of Participants Maintaining Relative Dose Intensity of CHOP Chemotherapy
Doxorubicin
|
88.6 Percentage of participants
|
77.4 Percentage of participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Safety: Percentage of Participants Maintaining Relative Dose Intensity of CHOP Chemotherapy
Vincristine
|
86.6 Percentage of participants
|
78.1 Percentage of participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
|
Safety: Percentage of Participants Maintaining Relative Dose Intensity of CHOP Chemotherapy
Prednisone
|
87.4 Percentage of participants
|
81.3 Percentage of participants
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
SECONDARY outcome
Timeframe: Baseline up to Cycle 6 (cycle length = 21 days)Population: Safety population: All patients who enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population for safety analyses
Dose intensity was categorized as \< 80%, 80% to \< 85%, 85% to \< 90%, or \>/= 90%.
Outcome measures
| Measure |
Venetoclax 200 mg + R-CHOP
n=7 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 400 mg + R-CHOP
n=3 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 600 mg + R-CHOP
n=8 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800mg + R-CHOP
n=6 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 200mg + G-CHOP
n=208 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 400mg + G-CHOP
n=7 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 600mg + G-CHOP
n=7 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg + G-CHOP A
n=6 Participants
Venetoclax + G-CHOP 800 mg A Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. In this arm venetoclax was delivered in Cycle 1 on Days 4-10 and Cycles 2-8 on Days 1-10. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg + G-CHOP B
n=6 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. In this arm ventoclax was delivered in Cycle 1 on Days 4-8 and Cycles 2-8 on Days 1-5. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg + G-CHOP B
n=6 Participants
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. In this arm ventoclax was delivered in Cycle 1 on Days 4-8 and Cycles 2-8 on Days 1-5. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Relative Dose Intensity of Venetoclax
<80%
|
71.4 Percentage of Partcipants
|
0.00 Percentage of Partcipants
|
12.5 Percentage of Partcipants
|
0.00 Percentage of Partcipants
|
26.0 Percentage of Partcipants
|
100.00 Percentage of Partcipants
|
14.3 Percentage of Partcipants
|
50.0 Percentage of Partcipants
|
83.3 Percentage of Partcipants
|
100.0 Percentage of Partcipants
|
|
Relative Dose Intensity of Venetoclax
80-<85%
|
0.00 Percentage of Partcipants
|
0.00 Percentage of Partcipants
|
12.5 Percentage of Partcipants
|
0.00 Percentage of Partcipants
|
3.4 Percentage of Partcipants
|
0.00 Percentage of Partcipants
|
14.3 Percentage of Partcipants
|
16.7 Percentage of Partcipants
|
0.00 Percentage of Partcipants
|
0.00 Percentage of Partcipants
|
|
Relative Dose Intensity of Venetoclax
85-<90%
|
0.00 Percentage of Partcipants
|
0.00 Percentage of Partcipants
|
12.5 Percentage of Partcipants
|
0.00 Percentage of Partcipants
|
2.9 Percentage of Partcipants
|
0.00 Percentage of Partcipants
|
0.00 Percentage of Partcipants
|
0.00 Percentage of Partcipants
|
16.7 Percentage of Partcipants
|
0.00 Percentage of Partcipants
|
|
Relative Dose Intensity of Venetoclax
>=90%
|
28.6 Percentage of Partcipants
|
100.00 Percentage of Partcipants
|
62.5 Percentage of Partcipants
|
100.00 Percentage of Partcipants
|
67.6 Percentage of Partcipants
|
0.00 Percentage of Partcipants
|
71.4 Percentage of Partcipants
|
33.3 Percentage of Partcipants
|
0.00 Percentage of Partcipants
|
0.00 Percentage of Partcipants
|
Adverse Events
Venetoclax 200 mg +R-CHOP
Serious events: 5 serious events
Other events: 7 other events
Deaths: 1 deaths
Venetoclax 400 mg +R-CHOP
Serious events: 2 serious events
Other events: 3 other events
Deaths: 0 deaths
Venetoclax 600 mg +R-CHOP
Serious events: 4 serious events
Other events: 8 other events
Deaths: 1 deaths
Venetoclax 800 mg +R-CHOP
Serious events: 3 serious events
Other events: 6 other events
Deaths: 4 deaths
Venetoclax 800 mg +R-CHOP Phase II
Serious events: 116 serious events
Other events: 204 other events
Deaths: 33 deaths
Venetoclax 200 mg +G-CHOP
Serious events: 5 serious events
Other events: 7 other events
Deaths: 1 deaths
Venetoclax 400 mg +G-CHOP
Serious events: 4 serious events
Other events: 7 other events
Deaths: 1 deaths
Venetoclax 600 mg +G-CHOP
Serious events: 3 serious events
Other events: 6 other events
Deaths: 0 deaths
Venetoclax 800 mg + G-CHOP A
Serious events: 5 serious events
Other events: 6 other events
Deaths: 0 deaths
Venetoclax 800 mg +G-CHOP B
Serious events: 5 serious events
Other events: 6 other events
Deaths: 0 deaths
Serious adverse events
| Measure |
Venetoclax 200 mg +R-CHOP
n=7 participants at risk
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 400 mg +R-CHOP
n=3 participants at risk
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 600 mg +R-CHOP
n=8 participants at risk
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg +R-CHOP
n=6 participants at risk
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg +R-CHOP Phase II
n=208 participants at risk
Phase II: Participants received 6 cycles of CHOP and 8 cycles of venetoclax (at dose determined in Phase I) + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 200 mg +G-CHOP
n=7 participants at risk
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 400 mg +G-CHOP
n=7 participants at risk
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 600 mg +G-CHOP
n=6 participants at risk
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg + G-CHOP A
n=6 participants at risk
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. In this arm venetoclax was administered as follows: Cycle 1 Days 4-10; Cycles 2-8 Days 1-10, Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg +G-CHOP B
n=6 participants at risk
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. In this arm venetoclax was administered as follows: Cycle 1 Days 4-8; Cycles 2-8 Days 1-5. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Cardiac disorders
SUPRAVENTRICULAR TACHYCARDIA
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Cardiac disorders
TACHYCARDIA
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Musculoskeletal and connective tissue disorders
JOINT SWELLING
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Blood and lymphatic system disorders
AGRANULOCYTOSIS
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Blood and lymphatic system disorders
ANAEMIA
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
33.3%
1/3 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
1.9%
4/208 • Number of events 4 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Blood and lymphatic system disorders
FEBRILE NEUTROPENIA
|
42.9%
3/7 • Number of events 5 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
12.5%
1/8 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
33.3%
2/6 • Number of events 3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
27.4%
57/208 • Number of events 89 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
28.6%
2/7 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Blood and lymphatic system disorders
HAEMOLYTIC ANAEMIA
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Blood and lymphatic system disorders
LEUKOPENIA
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Blood and lymphatic system disorders
NEUTROPENIA
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
9.1%
19/208 • Number of events 24 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Blood and lymphatic system disorders
THROMBOCYTOPENIA
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.96%
2/208 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
33.3%
2/6 • Number of events 4 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Cardiac disorders
ACUTE CORONARY SYNDROME
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Cardiac disorders
ATRIAL FIBRILLATION
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
33.3%
1/3 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
2.9%
6/208 • Number of events 6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Cardiac disorders
ATRIOVENTRICULAR BLOCK
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.96%
2/208 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Cardiac disorders
CARDIAC ARREST
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Cardiac disorders
CARDIAC FAILURE
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Cardiac disorders
CARDIAC FAILURE CONGESTIVE
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Cardiac disorders
CARDIOGENIC SHOCK
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Cardiac disorders
CARDIOMYOPATHY
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
33.3%
1/3 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Cardiac disorders
LEFT VENTRICULAR FAILURE
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Cardiac disorders
MYOCARDIAL ISCHAEMIA
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Cardiac disorders
SINUS TACHYCARDIA
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Eye disorders
OPTIC NEUROPATHY
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Gastrointestinal disorders
DIARRHOEA
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
1.9%
4/208 • Number of events 4 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Gastrointestinal disorders
DIVERTICULAR PERFORATION
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Gastrointestinal disorders
DUODENAL STENOSIS
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Gastrointestinal disorders
DYSPHAGIA
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Gastrointestinal disorders
ENTEROCOLITIS
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Gastrointestinal disorders
GASTRIC DILATATION
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Gastrointestinal disorders
GASTRIC PERFORATION
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Gastrointestinal disorders
GASTRIC STENOSIS
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Gastrointestinal disorders
GASTRIC ULCER
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Gastrointestinal disorders
GASTRIC ULCER PERFORATION
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Gastrointestinal disorders
GASTROINTESTINAL PAIN
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Gastrointestinal disorders
HAEMATEMESIS
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Gastrointestinal disorders
ILEAL PERFORATION
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Gastrointestinal disorders
ILEUS
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Gastrointestinal disorders
NAUSEA
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Gastrointestinal disorders
OBSTRUCTION GASTRIC
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Gastrointestinal disorders
OESOPHAGEAL STENOSIS
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Gastrointestinal disorders
PANCREATITIS
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.96%
2/208 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Gastrointestinal disorders
RECTAL HAEMORRHAGE
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Gastrointestinal disorders
SMALL INTESTINAL OBSTRUCTION
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Gastrointestinal disorders
STOMATITIS
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Gastrointestinal disorders
UPPER GASTROINTESTINAL HAEMORRHAGE
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Gastrointestinal disorders
VOMITING
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
33.3%
1/3 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
2.4%
5/208 • Number of events 5 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
General disorders
ASTHENIA
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
General disorders
FATIGUE
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.96%
2/208 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
General disorders
INFLAMMATION
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
General disorders
PYREXIA
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
3.4%
7/208 • Number of events 7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
General disorders
SUDDEN CARDIAC DEATH
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Hepatobiliary disorders
BILE DUCT STONE
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Hepatobiliary disorders
CHOLECYSTITIS
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Hepatobiliary disorders
CHOLECYSTITIS ACUTE
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Hepatobiliary disorders
DRUG-INDUCED LIVER INJURY
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Immune system disorders
HYPOGAMMAGLOBULINAEMIA
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Infections and infestations
ACUTE SINUSITIS
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Infections and infestations
ATYPICAL PNEUMONIA
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.96%
2/208 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Infections and infestations
BACTERIAL SEPSIS
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Infections and infestations
BRONCHITIS
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Infections and infestations
CELLULITIS
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Infections and infestations
CLOSTRIDIUM COLITIS
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Infections and infestations
CLOSTRIDIUM DIFFICILE INFECTION
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Infections and infestations
DEVICE RELATED INFECTION
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Infections and infestations
DIVERTICULITIS
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Infections and infestations
EMPYEMA
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Infections and infestations
ESCHERICHIA PYELONEPHRITIS
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Infections and infestations
ESCHERICHIA URINARY TRACT INFECTION
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Infections and infestations
GASTROENTERITIS
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Infections and infestations
GASTROENTERITIS NOROVIRUS
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Infections and infestations
HERPES SIMPLEX
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Infections and infestations
INFECTION
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
1.9%
4/208 • Number of events 5 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Infections and infestations
INFLUENZA
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.96%
2/208 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Infections and infestations
LOWER RESPIRATORY TRACT INFECTION
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.96%
2/208 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Infections and infestations
LUNG INFECTION
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
1.4%
3/208 • Number of events 4 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Infections and infestations
MENINGITIS VIRAL
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Infections and infestations
NASOPHARYNGITIS
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Infections and infestations
OOPHORITIS
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Infections and infestations
ORAL CANDIDIASIS
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Infections and infestations
ORAL HERPES
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Infections and infestations
PNEUMOCYSTIS JIROVECII INFECTION
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Infections and infestations
PNEUMOCYSTIS JIROVECII PNEUMONIA
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.96%
2/208 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Infections and infestations
PNEUMONIA
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
4.3%
9/208 • Number of events 9 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Infections and infestations
PNEUMONIA RESPIRATORY SYNCYTIAL VIRAL
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Infections and infestations
PSEUDOMONAL SEPSIS
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.96%
2/208 • Number of events 3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Infections and infestations
RECTAL ABSCESS
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Infections and infestations
RESPIRATORY TRACT INFECTION
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Infections and infestations
RHINOVIRUS INFECTION
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
12.5%
1/8 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Infections and infestations
SEPSIS
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
2.9%
6/208 • Number of events 6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Infections and infestations
SIALOADENITIS
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Infections and infestations
SINUSITIS
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Infections and infestations
SKIN INFECTION
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Infections and infestations
STAPHYLOCOCCAL SEPSIS
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Infections and infestations
UPPER RESPIRATORY TRACT INFECTION
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Infections and infestations
URINARY TRACT INFECTION
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.96%
2/208 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Infections and infestations
URINARY TRACT INFECTION PSEUDOMONAL
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Infections and infestations
VASCULAR DEVICE INFECTION
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.96%
2/208 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Injury, poisoning and procedural complications
CONTUSION
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Injury, poisoning and procedural complications
INFUSION RELATED REACTION
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
12.5%
1/8 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Injury, poisoning and procedural complications
LIGAMENT RUPTURE
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
12.5%
1/8 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Injury, poisoning and procedural complications
POST LUMBAR PUNCTURE SYNDROME
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Injury, poisoning and procedural complications
SPINAL FRACTURE
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Injury, poisoning and procedural complications
TOXICITY TO VARIOUS AGENTS
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Investigations
BLOOD POTASSIUM INCREASED
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Investigations
C-REACTIVE PROTEIN INCREASED
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Metabolism and nutrition disorders
DECREASED APPETITE
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Metabolism and nutrition disorders
DEHYDRATION
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Metabolism and nutrition disorders
DIABETES MELLITUS INADEQUATE CONTROL
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.96%
2/208 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Metabolism and nutrition disorders
HYPERKALAEMIA
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Metabolism and nutrition disorders
HYPOKALAEMIA
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Metabolism and nutrition disorders
HYPONATRAEMIA
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Metabolism and nutrition disorders
TUMOUR LYSIS SYNDROME
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
12.5%
1/8 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Musculoskeletal and connective tissue disorders
BACK PAIN
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Musculoskeletal and connective tissue disorders
PAIN IN EXTREMITY
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.96%
2/208 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Musculoskeletal and connective tissue disorders
SPONDYLOLISTHESIS
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
ACUTE MYELOID LEUKAEMIA
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
1.4%
3/208 • Number of events 3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
ADENOLYMPHOMA
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
GLIOBLASTOMA
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
HISTIOCYTOSIS
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
LUNG NEOPLASM MALIGNANT
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
MYELODYSPLASTIC SYNDROME
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
12.5%
1/8 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.96%
2/208 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Nervous system disorders
CAROTID SINUS SYNDROME
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Nervous system disorders
EPILEPSY
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Nervous system disorders
HYPOGLOSSAL NERVE PARESIS
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Nervous system disorders
POLYNEUROPATHY
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Nervous system disorders
PRESYNCOPE
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Nervous system disorders
SYNCOPE
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.96%
2/208 • Number of events 3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Nervous system disorders
TRANSIENT ISCHAEMIC ATTACK
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Psychiatric disorders
CONFUSIONAL STATE
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Psychiatric disorders
PSYCHOTIC DISORDER
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Renal and urinary disorders
ACUTE KIDNEY INJURY
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.96%
2/208 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Respiratory, thoracic and mediastinal disorders
CHRONIC OBSTRUCTIVE PULMONARY DISEASE
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Respiratory, thoracic and mediastinal disorders
COUGH
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Respiratory, thoracic and mediastinal disorders
DYSPNOEA
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.96%
2/208 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Respiratory, thoracic and mediastinal disorders
HAEMOPTYSIS
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Respiratory, thoracic and mediastinal disorders
INTERSTITIAL LUNG DISEASE
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
12.5%
1/8 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Respiratory, thoracic and mediastinal disorders
ORGANISING PNEUMONIA
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Respiratory, thoracic and mediastinal disorders
PLEURAL EFFUSION
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Respiratory, thoracic and mediastinal disorders
PNEUMOTHORAX
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Respiratory, thoracic and mediastinal disorders
PRODUCTIVE COUGH
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Respiratory, thoracic and mediastinal disorders
PULMONARY EMBOLISM
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Skin and subcutaneous tissue disorders
RASH MACULO-PAPULAR
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Vascular disorders
EMBOLISM
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Vascular disorders
HYPOTENSION
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.96%
2/208 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
Other adverse events
| Measure |
Venetoclax 200 mg +R-CHOP
n=7 participants at risk
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 400 mg +R-CHOP
n=3 participants at risk
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 600 mg +R-CHOP
n=8 participants at risk
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg +R-CHOP
n=6 participants at risk
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg +R-CHOP Phase II
n=208 participants at risk
Phase II: Participants received 6 cycles of CHOP and 8 cycles of venetoclax (at dose determined in Phase I) + rituximab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 200 mg +G-CHOP
n=7 participants at risk
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 400 mg +G-CHOP
n=7 participants at risk
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 600 mg +G-CHOP
n=6 participants at risk
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg + G-CHOP A
n=6 participants at risk
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. In this arm venetoclax was administered as follows: Cycle 1 Days 4-10; Cycles 2-8 Days 1-10, Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
Venetoclax 800 mg +G-CHOP B
n=6 participants at risk
Phase I: Participants received 6 cycles of CHOP and 8 cycles of venetoclax + obinutuzumab. Each cycle consisted of 21 days. In this arm venetoclax was administered as follows: Cycle 1 Days 4-8; Cycles 2-8 Days 1-5. Participants who experienced ongoing response without excessive toxicity could receive up to eight cycles of CHOP following discussion between the investigator and the Medical Monitor.
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Blood and lymphatic system disorders
LEUKOPENIA
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
11.1%
23/208 • Number of events 47 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Infections and infestations
CELLULITIS ORBITAL
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Blood and lymphatic system disorders
NEUTROPENIA
|
57.1%
4/7 • Number of events 9 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
66.7%
2/3 • Number of events 8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
75.0%
6/8 • Number of events 18 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
50.0%
3/6 • Number of events 10 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
64.4%
134/208 • Number of events 409 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
28.6%
2/7 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
57.1%
4/7 • Number of events 17 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
83.3%
5/6 • Number of events 13 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
100.0%
6/6 • Number of events 16 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
33.3%
2/6 • Number of events 10 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Blood and lymphatic system disorders
PANCYTOPENIA
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
12.5%
1/8 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Nervous system disorders
AGEUSIA
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Infections and infestations
CLOSTRIDIUM DIFFICILE COLITIS
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
1.4%
3/208 • Number of events 3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Blood and lymphatic system disorders
ANAEMIA
|
57.1%
4/7 • Number of events 9 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
12.5%
1/8 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
33.3%
2/6 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
35.1%
73/208 • Number of events 117 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 4 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
83.3%
5/6 • Number of events 8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
66.7%
4/6 • Number of events 5 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Blood and lymphatic system disorders
FEBRILE NEUTROPENIA
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
12.5%
1/8 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
4.3%
9/208 • Number of events 10 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
57.1%
4/7 • Number of events 7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Blood and lymphatic system disorders
HAEMOLYTIC ANAEMIA
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Blood and lymphatic system disorders
THROMBOCYTOPENIA
|
57.1%
4/7 • Number of events 7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
33.3%
1/3 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
37.5%
3/8 • Number of events 5 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
25.0%
52/208 • Number of events 89 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
28.6%
2/7 • Number of events 3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
42.9%
3/7 • Number of events 7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
33.3%
2/6 • Number of events 6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
66.7%
4/6 • Number of events 15 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
33.3%
2/6 • Number of events 5 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Cardiac disorders
ANGINA PECTORIS
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Cardiac disorders
ATRIAL FIBRILLATION
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
12.5%
1/8 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
3.4%
7/208 • Number of events 8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Cardiac disorders
CARDIAC FAILURE
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Cardiac disorders
PALPITATIONS
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
12.5%
1/8 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
3.8%
8/208 • Number of events 8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Cardiac disorders
TACHYCARDIA
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
12.5%
1/8 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
1.4%
3/208 • Number of events 3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Congenital, familial and genetic disorders
ICHTHYOSIS
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
12.5%
1/8 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Ear and labyrinth disorders
EAR PAIN
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Ear and labyrinth disorders
TINNITUS
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Eye disorders
DRY EYE
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
1.9%
4/208 • Number of events 4 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Eye disorders
EYE PAIN
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Eye disorders
LACRIMATION INCREASED
|
28.6%
2/7 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
1.4%
3/208 • Number of events 3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Eye disorders
PHOTOPHOBIA
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Eye disorders
VISION BLURRED
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
12.5%
1/8 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
3.4%
7/208 • Number of events 7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Eye disorders
VITREOUS FLOATERS
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Gastrointestinal disorders
ABDOMINAL DISCOMFORT
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
1.9%
4/208 • Number of events 4 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Gastrointestinal disorders
ABDOMINAL DISTENSION
|
28.6%
2/7 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
6.7%
14/208 • Number of events 15 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Gastrointestinal disorders
ABDOMINAL PAIN
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
12.5%
1/8 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.4%
30/208 • Number of events 38 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
50.0%
3/6 • Number of events 4 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Gastrointestinal disorders
ABDOMINAL PAIN UPPER
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
33.3%
1/3 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
12.5%
1/8 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
3.4%
7/208 • Number of events 12 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Gastrointestinal disorders
CONSTIPATION
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
66.7%
2/3 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
37.5%
3/8 • Number of events 3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
33.3%
2/6 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
32.2%
67/208 • Number of events 78 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
85.7%
6/7 • Number of events 7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
42.9%
3/7 • Number of events 3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
33.3%
2/6 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
33.3%
2/6 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Gastrointestinal disorders
DENTAL CARIES
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Gastrointestinal disorders
DENTAL CYST
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Gastrointestinal disorders
DIARRHOEA
|
42.9%
3/7 • Number of events 10 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
66.7%
2/3 • Number of events 4 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
25.0%
2/8 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
50.0%
3/6 • Number of events 5 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
38.0%
79/208 • Number of events 133 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
71.4%
5/7 • Number of events 5 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
42.9%
3/7 • Number of events 6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
33.3%
2/6 • Number of events 3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
33.3%
2/6 • Number of events 4 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Gastrointestinal disorders
DRY MOUTH
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
2.4%
5/208 • Number of events 5 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Gastrointestinal disorders
DYSPEPSIA
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
33.3%
1/3 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
10.6%
22/208 • Number of events 27 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Gastrointestinal disorders
DYSPHAGIA
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
3.4%
7/208 • Number of events 9 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Gastrointestinal disorders
FLATULENCE
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
1.9%
4/208 • Number of events 4 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Gastrointestinal disorders
GASTRIC ULCER
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Gastrointestinal disorders
GASTROINTESTINAL DISORDER
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Gastrointestinal disorders
GASTROOESOPHAGEAL REFLUX DISEASE
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
12.5%
1/8 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
33.3%
2/6 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
2.9%
6/208 • Number of events 7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Gastrointestinal disorders
GINGIVAL PAIN
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Gastrointestinal disorders
HAEMORRHOIDS
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
7.2%
15/208 • Number of events 17 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Gastrointestinal disorders
MOUTH ULCERATION
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
12.5%
1/8 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
3.4%
7/208 • Number of events 7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Gastrointestinal disorders
NAUSEA
|
42.9%
3/7 • Number of events 3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
66.7%
2/3 • Number of events 4 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
12.5%
1/8 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
83.3%
5/6 • Number of events 7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
51.9%
108/208 • Number of events 172 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
42.9%
3/7 • Number of events 5 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
57.1%
4/7 • Number of events 7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
50.0%
3/6 • Number of events 4 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
83.3%
5/6 • Number of events 10 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
66.7%
4/6 • Number of events 6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Gastrointestinal disorders
ORAL PAIN
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
1.4%
3/208 • Number of events 3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Gastrointestinal disorders
PROCTALGIA
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.96%
2/208 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Gastrointestinal disorders
STOMATITIS
|
28.6%
2/7 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
33.3%
1/3 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
12.5%
1/8 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
33.3%
2/6 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
11.5%
24/208 • Number of events 29 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Gastrointestinal disorders
TOOTHACHE
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.96%
2/208 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Gastrointestinal disorders
VOMITING
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
33.3%
1/3 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
12.5%
1/8 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
33.3%
2/6 • Number of events 6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
30.8%
64/208 • Number of events 111 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
71.4%
5/7 • Number of events 5 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
57.1%
4/7 • Number of events 8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
66.7%
4/6 • Number of events 6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
General disorders
ASTHENIA
|
28.6%
2/7 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
33.3%
1/3 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
25.0%
2/8 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
15.9%
33/208 • Number of events 41 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
28.6%
2/7 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
General disorders
CHEST PAIN
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
5.8%
12/208 • Number of events 12 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
General disorders
CHILLS
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
5.8%
12/208 • Number of events 15 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
General disorders
FATIGUE
|
71.4%
5/7 • Number of events 5 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
37.5%
3/8 • Number of events 3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
33.3%
2/6 • Number of events 4 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
38.9%
81/208 • Number of events 104 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
71.4%
5/7 • Number of events 7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
28.6%
2/7 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
33.3%
2/6 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
50.0%
3/6 • Number of events 4 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
General disorders
FEELING ABNORMAL
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
General disorders
GAIT DISTURBANCE
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
1.4%
3/208 • Number of events 3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
General disorders
INFLUENZA LIKE ILLNESS
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
1.4%
3/208 • Number of events 4 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
General disorders
INFUSION SITE EXTRAVASATION
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
General disorders
MALAISE
|
28.6%
2/7 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
2.4%
5/208 • Number of events 5 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
General disorders
MUCOSAL INFLAMMATION
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
25.0%
2/8 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
9.1%
19/208 • Number of events 28 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
42.9%
3/7 • Number of events 3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
General disorders
NON-CARDIAC CHEST PAIN
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
General disorders
OEDEMA
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
1.4%
3/208 • Number of events 4 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
General disorders
OEDEMA PERIPHERAL
|
28.6%
2/7 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
25.0%
2/8 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
11.1%
23/208 • Number of events 26 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
50.0%
3/6 • Number of events 3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
General disorders
PAIN
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
3.4%
7/208 • Number of events 8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
33.3%
2/6 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
General disorders
PYREXIA
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
12.5%
1/8 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
33.3%
2/6 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
24.0%
50/208 • Number of events 68 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
71.4%
5/7 • Number of events 7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
33.3%
2/6 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
33.3%
2/6 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
General disorders
UNEVALUABLE EVENT
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Hepatobiliary disorders
CHOLELITHIASIS
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Hepatobiliary disorders
HYPERBILIRUBINAEMIA
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
1.4%
3/208 • Number of events 5 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Immune system disorders
HYPERSENSITIVITY
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Immune system disorders
HYPOGAMMAGLOBULINAEMIA
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Infections and infestations
ANORECTAL INFECTION
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Infections and infestations
BRONCHITIS
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
12.5%
1/8 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
7.7%
16/208 • Number of events 18 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Infections and infestations
CAMPYLOBACTER GASTROENTERITIS
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
12.5%
1/8 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Infections and infestations
CANDIDA INFECTION
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
1.4%
3/208 • Number of events 3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Infections and infestations
CELLULITIS
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Infections and infestations
CLOSTRIDIUM DIFFICILE INFECTION
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Infections and infestations
CONJUNCTIVITIS
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.96%
2/208 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Infections and infestations
DEVICE RELATED INFECTION
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Infections and infestations
ENTEROVIRUS INFECTION
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Infections and infestations
ERYSIPELAS
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Infections and infestations
FURUNCLE
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Infections and infestations
HERPES SIMPLEX
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Infections and infestations
HERPES ZOSTER
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Infections and infestations
INFLUENZA
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.96%
2/208 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Infections and infestations
LUNG INFECTION
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
1.9%
4/208 • Number of events 5 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Infections and infestations
NASOPHARYNGITIS
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
3.8%
8/208 • Number of events 9 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Infections and infestations
ORAL CANDIDIASIS
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
3.8%
8/208 • Number of events 9 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Infections and infestations
ORAL FUNGAL INFECTION
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.96%
2/208 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Infections and infestations
ORAL HERPES
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
2.4%
5/208 • Number of events 6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Infections and infestations
PNEUMOCYSTIS JIROVECII PNEUMONIA
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Infections and infestations
PNEUMONIA
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
2.4%
5/208 • Number of events 5 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Infections and infestations
PSEUDOMONAL BACTERAEMIA
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Infections and infestations
RHINITIS
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
3.4%
7/208 • Number of events 7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Infections and infestations
SEPSIS
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Infections and infestations
SINUSITIS BACTERIAL
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Infections and infestations
SKIN INFECTION
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
1.4%
3/208 • Number of events 3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Infections and infestations
STAPHYLOCOCCAL INFECTION
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Infections and infestations
TOOTH ABSCESS
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Infections and infestations
UPPER RESPIRATORY TRACT INFECTION
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
5.8%
12/208 • Number of events 15 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
28.6%
2/7 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Infections and infestations
URINARY TRACT INFECTION
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
7.7%
16/208 • Number of events 22 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Infections and infestations
VASCULAR DEVICE INFECTION
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Infections and infestations
VIRAL UPPER RESPIRATORY TRACT INFECTION
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
12.5%
1/8 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Infections and infestations
VULVOVAGINAL CANDIDIASIS
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Injury, poisoning and procedural complications
FALL
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
1.9%
4/208 • Number of events 4 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Injury, poisoning and procedural complications
HAND FRACTURE
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Injury, poisoning and procedural complications
INFUSION RELATED REACTION
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
66.7%
2/3 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
12.5%
1/8 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
33.3%
2/6 • Number of events 3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
21.2%
44/208 • Number of events 48 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
57.1%
4/7 • Number of events 4 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
33.3%
2/6 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
33.3%
2/6 • Number of events 3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
50.0%
3/6 • Number of events 4 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Injury, poisoning and procedural complications
MUSCLE STRAIN
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
12.5%
1/8 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Injury, poisoning and procedural complications
PROCEDURAL PAIN
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Injury, poisoning and procedural complications
THERMAL BURN
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Injury, poisoning and procedural complications
TRACHEAL OBSTRUCTION
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
12.5%
1/8 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Investigations
ALANINE AMINOTRANSFERASE INCREASED
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Investigations
ASPARTATE AMINOTRANSFERASE INCREASED
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Investigations
BLOOD MAGNESIUM DECREASED
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Investigations
BLOOD POTASSIUM INCREASED
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Investigations
COMPUTERISED TOMOGRAM THORAX ABNORMAL
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Investigations
EJECTION FRACTION DECREASED
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.96%
2/208 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Investigations
URINE OUTPUT DECREASED
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Investigations
WEIGHT DECREASED
|
28.6%
2/7 • Number of events 3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
15.4%
32/208 • Number of events 33 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
33.3%
2/6 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Investigations
WEIGHT INCREASED
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
1.4%
3/208 • Number of events 3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Investigations
WHITE BLOOD CELL COUNT DECREASED
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Metabolism and nutrition disorders
DECREASED APPETITE
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
33.3%
1/3 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
12.5%
1/8 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
20.2%
42/208 • Number of events 45 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
28.6%
2/7 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
28.6%
2/7 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
33.3%
2/6 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Metabolism and nutrition disorders
DEHYDRATION
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
3.4%
7/208 • Number of events 11 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Metabolism and nutrition disorders
FLUID RETENTION
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.96%
2/208 • Number of events 3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Metabolism and nutrition disorders
GOUT
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.96%
2/208 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Metabolism and nutrition disorders
HYPERKALAEMIA
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
1.9%
4/208 • Number of events 4 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Metabolism and nutrition disorders
HYPERPHOSPHATAEMIA
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.96%
2/208 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Metabolism and nutrition disorders
HYPERURICAEMIA
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
12.5%
1/8 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.96%
2/208 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Metabolism and nutrition disorders
HYPOCALCAEMIA
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
1.4%
3/208 • Number of events 4 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Metabolism and nutrition disorders
HYPOCHLORAEMIA
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Metabolism and nutrition disorders
HYPOKALAEMIA
|
42.9%
3/7 • Number of events 4 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
33.3%
1/3 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
25.0%
2/8 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.8%
35/208 • Number of events 44 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
28.6%
2/7 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Metabolism and nutrition disorders
HYPOMAGNESAEMIA
|
14.3%
1/7 • Number of events 6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
4.8%
10/208 • Number of events 12 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Metabolism and nutrition disorders
HYPONATRAEMIA
|
14.3%
1/7 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
1.9%
4/208 • Number of events 4 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Metabolism and nutrition disorders
HYPOPHOSPHATAEMIA
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
12.5%
1/8 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
3.4%
7/208 • Number of events 9 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Metabolism and nutrition disorders
TUMOUR LYSIS SYNDROME
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Musculoskeletal and connective tissue disorders
ARTHRALGIA
|
28.6%
2/7 • Number of events 4 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
10.6%
22/208 • Number of events 23 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
28.6%
2/7 • Number of events 3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Musculoskeletal and connective tissue disorders
BACK PAIN
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
12.5%
1/8 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
33.3%
2/6 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
13.9%
29/208 • Number of events 34 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
28.6%
2/7 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Musculoskeletal and connective tissue disorders
BONE PAIN
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
33.3%
1/3 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
4.3%
9/208 • Number of events 10 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
28.6%
2/7 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
33.3%
2/6 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Musculoskeletal and connective tissue disorders
MUSCLE SPASMS
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
12.5%
1/8 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
2.4%
5/208 • Number of events 5 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Musculoskeletal and connective tissue disorders
MUSCULAR WEAKNESS
|
28.6%
2/7 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
4.8%
10/208 • Number of events 10 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Musculoskeletal and connective tissue disorders
MUSCULOSKELETAL CHEST PAIN
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
1.4%
3/208 • Number of events 3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Musculoskeletal and connective tissue disorders
MYALGIA
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
12.5%
1/8 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
5.8%
12/208 • Number of events 18 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Musculoskeletal and connective tissue disorders
PAIN IN EXTREMITY
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
2.4%
5/208 • Number of events 5 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Musculoskeletal and connective tissue disorders
PAIN IN JAW
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
SQUAMOUS CELL CARCINOMA
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Neoplasms benign, malignant and unspecified (incl cysts and polyps)
SQUAMOUS CELL CARCINOMA OF SKIN
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Nervous system disorders
CAROTID SINUS SYNDROME
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Nervous system disorders
COGNITIVE DISORDER
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Nervous system disorders
DISTURBANCE IN ATTENTION
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Nervous system disorders
DIZZINESS
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
25.0%
2/8 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
11.5%
24/208 • Number of events 33 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
33.3%
2/6 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Nervous system disorders
DYSGEUSIA
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
12.5%
1/8 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
9.1%
19/208 • Number of events 19 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
42.9%
3/7 • Number of events 3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
33.3%
2/6 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
66.7%
4/6 • Number of events 4 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Nervous system disorders
HEADACHE
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
37.5%
3/8 • Number of events 3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
13.5%
28/208 • Number of events 31 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
42.9%
3/7 • Number of events 5 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
42.9%
3/7 • Number of events 3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Nervous system disorders
HYPOAESTHESIA
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
1.9%
4/208 • Number of events 4 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Nervous system disorders
LETHARGY
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Nervous system disorders
MEMORY IMPAIRMENT
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
1.4%
3/208 • Number of events 3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Nervous system disorders
NEUROPATHY PERIPHERAL
|
28.6%
2/7 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
33.3%
1/3 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
37.5%
3/8 • Number of events 3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
50.0%
3/6 • Number of events 3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
13.5%
28/208 • Number of events 33 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
28.6%
2/7 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
33.3%
2/6 • Number of events 3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Nervous system disorders
PARAESTHESIA
|
28.6%
2/7 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
8.7%
18/208 • Number of events 26 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Nervous system disorders
PERIPHERAL MOTOR NEUROPATHY
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.96%
2/208 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Nervous system disorders
PERIPHERAL SENSORY NEUROPATHY
|
42.9%
3/7 • Number of events 3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
33.3%
1/3 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
25.0%
2/8 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
33.3%
2/6 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
6.7%
14/208 • Number of events 14 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Nervous system disorders
POST HERPETIC NEURALGIA
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Nervous system disorders
PRESYNCOPE
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
12.5%
1/8 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Nervous system disorders
SYNCOPE
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
1.9%
4/208 • Number of events 8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Psychiatric disorders
ANXIETY
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
4.3%
9/208 • Number of events 9 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Psychiatric disorders
DEPRESSION
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
1.9%
4/208 • Number of events 5 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Psychiatric disorders
INSOMNIA
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
25.0%
2/8 • Number of events 3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
6.7%
14/208 • Number of events 17 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
28.6%
2/7 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
28.6%
2/7 • Number of events 3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Psychiatric disorders
MOOD SWINGS
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Renal and urinary disorders
BLADDER HYPERTROPHY
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Renal and urinary disorders
DYSURIA
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
33.3%
1/3 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
1.4%
3/208 • Number of events 3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Renal and urinary disorders
HAEMATURIA
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Renal and urinary disorders
NOCTURIA
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Renal and urinary disorders
POLLAKIURIA
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Renal and urinary disorders
RENAL FAILURE
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Renal and urinary disorders
URINARY INCONTINENCE
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.96%
2/208 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Renal and urinary disorders
URINARY TRACT PAIN
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Reproductive system and breast disorders
BREAST PAIN
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Reproductive system and breast disorders
TESTICULAR PAIN
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Reproductive system and breast disorders
VAGINAL DISCHARGE
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Reproductive system and breast disorders
VULVOVAGINAL DRYNESS
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Respiratory, thoracic and mediastinal disorders
COUGH
|
28.6%
2/7 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
37.5%
3/8 • Number of events 4 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
24.5%
51/208 • Number of events 67 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
42.9%
3/7 • Number of events 3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
28.6%
2/7 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
50.0%
3/6 • Number of events 5 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
33.3%
2/6 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Respiratory, thoracic and mediastinal disorders
DYSPNOEA
|
28.6%
2/7 • Number of events 3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
33.3%
1/3 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
10.6%
22/208 • Number of events 24 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Respiratory, thoracic and mediastinal disorders
DYSPNOEA EXERTIONAL
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
33.3%
1/3 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
12.5%
1/8 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
1.9%
4/208 • Number of events 4 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Respiratory, thoracic and mediastinal disorders
EPISTAXIS
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
1.4%
3/208 • Number of events 3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Respiratory, thoracic and mediastinal disorders
HICCUPS
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
1.9%
4/208 • Number of events 5 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Respiratory, thoracic and mediastinal disorders
NASAL CONGESTION
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
12.5%
1/8 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
5.3%
11/208 • Number of events 11 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
28.6%
2/7 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
33.3%
2/6 • Number of events 4 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Respiratory, thoracic and mediastinal disorders
OROPHARYNGEAL PAIN
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
4.8%
10/208 • Number of events 13 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Respiratory, thoracic and mediastinal disorders
PLEURAL EFFUSION
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Respiratory, thoracic and mediastinal disorders
PLEURITIC PAIN
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Respiratory, thoracic and mediastinal disorders
PRODUCTIVE COUGH
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
3.8%
8/208 • Number of events 8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Respiratory, thoracic and mediastinal disorders
RHINORRHOEA
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
5.3%
11/208 • Number of events 11 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Respiratory, thoracic and mediastinal disorders
SINUS PAIN
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Respiratory, thoracic and mediastinal disorders
VOCAL CORD DYSFUNCTION
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Respiratory, thoracic and mediastinal disorders
WHEEZING
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Skin and subcutaneous tissue disorders
ALOPECIA
|
14.3%
1/7 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
50.0%
3/6 • Number of events 3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
13.5%
28/208 • Number of events 29 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Skin and subcutaneous tissue disorders
DRY SKIN
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
33.3%
1/3 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
3.8%
8/208 • Number of events 9 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
28.6%
2/7 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Skin and subcutaneous tissue disorders
ECCHYMOSIS
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Skin and subcutaneous tissue disorders
HYPERHIDROSIS
|
14.3%
1/7 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
1.4%
3/208 • Number of events 3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Skin and subcutaneous tissue disorders
NAIL DISCOLOURATION
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
12.5%
1/8 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
1.4%
3/208 • Number of events 3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Skin and subcutaneous tissue disorders
NIGHT SWEATS
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
1.9%
4/208 • Number of events 4 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Skin and subcutaneous tissue disorders
PIGMENTATION DISORDER
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/208 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Skin and subcutaneous tissue disorders
PRURITUS
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
33.3%
1/3 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
2.9%
6/208 • Number of events 8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Skin and subcutaneous tissue disorders
PURPURA
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Skin and subcutaneous tissue disorders
RASH
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
12.5%
1/8 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
4.3%
9/208 • Number of events 9 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Skin and subcutaneous tissue disorders
RASH MACULO-PAPULAR
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
2.4%
5/208 • Number of events 5 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
33.3%
2/6 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Skin and subcutaneous tissue disorders
SKIN HYPERPIGMENTATION
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.48%
1/208 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Vascular disorders
HOT FLUSH
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.96%
2/208 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Vascular disorders
HYPOTENSION
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
6.2%
13/208 • Number of events 15 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 2 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
|
Vascular disorders
THROMBOPHLEBITIS
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/8 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
16.7%
1/6 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
1.4%
3/208 • Number of events 3 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
14.3%
1/7 • Number of events 1 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/7 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
0.00%
0/6 • Baseline up to approximately 67 months
Safety population: All participants, who were enrolled in the study and received any amount of venetoclax or R-CHOP/G-CHOP were included in the safety population.
|
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.
- Publication restrictions are in place
Restriction type: OTHER